Analytical RnD has several years of experience in clinical analysis projects. We have highly qualified and specialized staff working on different clinical research and analysis. Our lab is equipped with advanced and modern instrumentation generating precise and accurate results.
Analytical RnD has extensive experience with preclinical clinical sample analysis. These include blood plasma and urine extraction, followed by LC-MS/MS high sensitivity analysis. A proficient preclinical partner facilitating drug discovery research with dedicated pK analysis and bio equivalence studies.
Benchmarking and redefining quality through NATA accreditation for GCLP principles and ISO 17025 certified facility for leveraging global data acceptability. Analytical RnD adds value through quality, reliability, flexibility, time management and cost-effectiveness.
Preclinical and Clinical
A proficient clinical and preclinical partner facilitating drug discovery research with dedicated in pK analysis and bio equivalence studies.
Our expertise are ;
Characterisation of drugs and their metabolite using high resolution mass spectrometry for the new drug discovery for new drug application.
Developing novel analytical techniques and methods in clinical research for some of the key projects include:
New assay development for NDA, including small molecules and peptides.
Lipid biomarkers supporting cancer research.
Peptide biomarkers for supporting cancer research,
Anti hypertension drugs
Steroids, steroid conjugates (glucuronides)
Cannabinoids testing, including THC, CBD, THCA-A, CBN
Amino acid assays
Fatty acids assays
Immunoassays using ELISA
Veterinary pharmaceutical such as antibiotics and anthelmintics
We offer comprehensive services including:
Lot release assays
Process and Product related impurity testing
Extractables & Leachables
Analytical RnD uses advanced analytical equipment to deliver the results for the tests mentioned above. These advanced mechinery include hihg resolution orbitraps (HRMS), GCMS/MS, UPLC, HPLC, GC, IC and many more.